GSK plc announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of Arexvy (respiratory syncytial virus vaccine,… read more.
A new study from the Texas A&M University School of Public Health found that only 9 percent of older Americans had been vaccinated against respiratory syncytial virus (RSV) prior to this fall and winter,… read more.
Peer-reviewed/Literature review and Modelling/People Acute lower respiratory infection caused by Respiratory Syncytial Virus (RSV) contributes substantially to the global mortality burden in children, with RSV estimated to cause one… read more.
Nearly one in ten of all deceased infants under 6 months old were infected with Respiratory Syncytial Virus. A new study found that nearly one in ten of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
